She received rituximab and bendamustine to treat chronic lymphocytic leukaemia. Adenopathy resolves with treatment and she does not experience any electrolyte disturbances or decrease in urine output as a result of chemotherapy in th...
- **D. 单药Rituximab**:患者已对单药耐药,再单用效果有限。 - **E. 放射免疫治疗+单药R**:广布病变不宜局部放疗,且单药R疗效不足。 综上,**R-Bendamustine(B)是最佳选择**。反馈 收藏
There has been an ongoing debate about whether such an aggressive chemotherapy combination is needed for these indolent lymphomas, Dr. Rummel noted. The updated results from the German Study Group for Indolent Lymphoma (StiL) "clearly show" that the simpler 2-drug combination of bendamustine plus ...
Michael Wang, MD Ibrutinib (Imbruvica) in combination with bendamustine (Bendeka) and rituximab (Rituxan) with rituximab maintenance elicited a significant improvement in progression-free survival (PFS) compared with standard chemoimmunotherapy in older patients with mantle cell lymphoma (MCL), ...
Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Wisconsin Oncology Network (WON) StudyChang C.KimR. S.Weiss
Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a rand...
以氯胺丁胺和苯达莫司汀为主的烷化剂被应用于CLL患者的治疗中,成为到目前为止,慢性淋巴细胞白血病(CLL)患者的标准疗法。另一种化疗药物,核苷类似物如氟达拉平、氯丙啶和戊妥他汀也在CLL患者中广泛应用。而化疗联合利妥昔单抗(rituximab)更可以达到91%的客观缓解率和44%的完全缓解率。
Bendamustine The risk or severity of adverse effects can be increased when Rituximab is combined with Bendamustine. Bendroflumethiazide Bendroflumethiazide may increase the hypotensive activities of Rituximab. Benralizumab The risk or severity of adverse effects can be increased when Rituximab is combin...
stimulating factors Bendamustine/rituximab/granulocyte colony stimulating factorsBendamustine/rituximab/granulocyte colony stimulating factorsReactions Weekly -doi:10.1007/s40278-017-32280-7NoneSpringer International PublishingReactions Weekly
Just by comparison, on the BR [bendamustine/rituximab] arm, the rate of MRD was only 2%, and they didn’t do much of an analysis among those patients because the numbers are so small. However, how to use it is still not entirely clear. And the reason is, as Matt has mentioned, ...